Kythera Biopharmaceuticals Inc  

(Public, NASDAQ:KYTH)   Watch this stock  
Find more results for KYTH
-1.20 (-2.89%)
After Hours: 40.35 0.00 (0.00%)
Mar 2, 5:09PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.12 - 43.22
52 week 29.50 - 53.61
Open 41.68
Vol / Avg. 471,457.00/224,873.00
Mkt cap 947.09M
P/E     -
Div/yield     -
EPS -5.69
Shares 22.68M
Beta     -
Inst. own 101%
Mar 2, 2015
Q4 2014 KYTHERA Biopharmaceuticals Inc Earnings Release (Estimated)
Feb 11, 2015
KYTHERA Biopharmaceuticals Inc at Leerink Global Healthcare Conference
Jan 12, 2015
KYTHERA Biopharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -69.20% -38.51%
Return on average equity -100.29% -47.46%
Employees 64 -
CDP Score - -


Suite 200 27200 West Agoura Road
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company�s initial focus is on the facial aesthetics market. The Company�s product candidate, ATX-101, is an injectable drug in late-stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The Company�s ATX-101 treatment contours the area under the chin by destroying fat cells while leaving surrounding tissue largely unaffected. The Company�s Phase II and Phase III studies have demonstrated that ATX-101, when injected subcutaneously into the target fat deposit, reduces the localized fat deposit while leaving the surrounding tissue largely unaffected. It is an attractive non-surgical solution for the reduction of submental fat.

Officers and directors

Keith R. Leonard Jr. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
John W. Smither Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Jeffrey D. Webster Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Keith L. Klein J.D. General Counsel
Age: 50
Bio & Compensation  - Reuters
Frederick Beddingfield III, M.D., Ph.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Hollings C. Renton III Director
Age: 64
Bio & Compensation  - Reuters
F. Michael Ball Independent Director
Age: 58
Bio & Compensation  - Reuters
Nathaniel E. David Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Francois Kress Independent Director
Age: 47
Bio & Compensation  - Reuters